We suppose that EPHA3 targets through the PI3K-Akt signaling pathway to wake up the antigen recognition of the immune-infiltrating cells (such as CD8+ cells) to achieve the purpose of killing the BLCA cells in vivo. The gene discussed is CD8A; the disease is bladder transitional cell carcinoma.